Our results confirm data from earlier studies that were obtained in breast, lung, and prostate cancer cell lines, in that high expression levels of caveolin-1, caveolin-2, annexin-1, moesin, Eph2A, and uPA were associated with in vitro sensitivity to dasatinib (Finn et al, 2007; Huang et al, 2007; Wang et al, 2007). The gene discussed is CAV2; the disease is prostate cancer.